AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 25194106
Drug: 540 mL
RxNorm normalized name: ALCOHOL 540 mL in 750 mL TOPICAL GEL [Wonder Hand Gel (Ethanol)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 540 mL bladder-filling protocol
Trial: 25194106
Drug: 1080 mL
RxNorm normalized name: pegcetacoplan
DrugBank: Pegcetacoplan (DB16694)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1080 mL bladder-filling protocol
Trial: 20385892
Drug: Glycopyrrolate 1
RxNorm normalized name: glycopyrrolate 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycopyrrolate 1 mg 3 times daily
Trial: 8035933
Drug: Entacapone (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entacapone (400 mg or 800 mg)
Trial: 8035933
Drug: Carbidopa (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa (150 mg) plus placebo
Trial: 8035933
Drug: Carbidopa (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carbidopa (150 mg) plus entacapone (400 mg or 800 mg)
Trial: 2564109
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy (5-fluorouracil and mitomycin C with or without induction course of 5-fluorouracil, vincristine, cyclophosphamide, and methotrexate)
Trial: 4772727
Drug: Benzhexol (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benzhexol (8 mg/day)
Trial: 29216779
Drug: Placebo (21.6%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (21.6% hydro-alcohol solution)
Trial: 27475733
Drug: Adjusted heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjusted heparin regimen
Trial: 27475733
Drug: Traditional heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional heparin regimen
Trial: 17971121
Drug: Two axial
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two axial grooves added to the crown preparation
Trial: 17971121
Drug: One axial
RxNorm normalized name: Gel-One
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One axial groove added to the crown preparation
Trial: 12810695
Drug: High-dose bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bolus interleukin-2 (IL-2) at a dosage of 600,000 U/kg every 8 hours on days 1 to 5 and days 15 to 19 (maximum 28 doses)
Trial: 12810695
Drug: High-dose bolus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose bolus interleukin-2 (IL-2)
Trial: 26464863
Drug: Rhubarb supplementation
RxNorm normalized name: RHUBARB
DrugBank: Rhubarb (DB10651)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rhubarb supplementation (350mg, thrice daily for 12 weeks)
Trial: 17403173
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid 10 mg 3 times a week immediately after every dialysis session
Trial: 17403173
Drug: Oral folic
RxNorm normalized name: folic acid Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral folic acid
Trial: 2095342
Drug: All doses
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All doses of Salbutamol
Trial: 873029
Drug: Tetrabid-Organon (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tetrabid-Organon (standard therapeutic doses)
Trial: 25996468
Drug: Facial‐Oral Tract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Facial‐Oral Tract Therapy (F.O.T.T.)
Trial: 19367397
Drug: Unfractionated heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin (UFH) 5,000 Units twice daily
Trial: 19367397
Drug: Low-molecular-weight heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-molecular-weight heparin (LMWH) enoxaparin 40 mg per day
Trial: 11198726
Drug: Cephalexin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cephalexin (500 mg three times daily for 7 days)
Trial: 2956200
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg nifedipine administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Trial: 2956200
Drug: Solvent administered
RxNorm normalized name: solvent yellow 18
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solvent administered intracoronarily before the first transluminal occlusion and again just before the second occlusion.
Trial: 2956200
Drug: 0.2 mg
RxNorm normalized name: niacin 0.2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2 mg nifedipine administered intracoronarily just before the second transluminal occlusion.
Trial: 26111347
Drug: Treatment adherence
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment adherence enhancement intervention
Trial: 10878419
Drug: Caffeine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Caffeine (2.5 mg/kg once a day)
Trial: 10878419
Drug: Aminophylline (1.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminophylline (1.25 mg/kg twice a day)
Trial: 1555424
Drug: Exosurf (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exosurf (5 ml/kg, intratracheal surfactant preparation)
Trial: 1555424
Drug: Air (5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Air (5 ml/kg, control group)
Trial: 3925478
Drug: Placebo (0.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (0.0 mg)
Trial: 18454655
Drug: SRP +
RxNorm normalized name: loratadine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SRP + doxycycline (100 mg/day for 14 days) (N = 15)
Trial: 16927289
Drug: Lamivudine treatment
RxNorm normalized name: Lamivudine
DrugBank: Lamivudine (DB00709)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Lamivudine treatment for longer than 1 year
Trial: 15725422
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg levodopa
Trial: 9061112
Drug: Bilateral maxillary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bilateral maxillary nerve block with local anaesthetics (5-10 ml of bupivacaine 0.5% and lignocaine 2%)
Trial: 8448063
Drug: 400 mg
RxNorm normalized name: mesna 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg carbamazepine liquid suspension
Trial: 8448063
Drug: Conventional tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional tablet formulation
Trial: 8448063
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release tablet formulation
Trial: 3492378
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg propyphenazone
Trial: 3492378
Drug: 300 mg
RxNorm normalized name: rutin 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg propyphenazone
Trial: 3178925
Drug: 1000 mg
RxNorm normalized name: bran 1000 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1000 mg acetylsalicylic acid (ASA)
Trial: 16898862
Drug: 3 oz
RxNorm normalized name: Oval Amber 3 oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 oz (84 g) of almonds daily for 4 weeks
Trial: 16898862
Drug: 6 oz
RxNorm normalized name: Oval Amber 16 oz
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 oz (168 g) of almonds daily for 4 weeks
Trial: 10802368
Drug: Concomitant boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant boost technique (CBT) radiation therapy, 46.8 Gy in 26 fractions with a concomitant boost of 18.2 Gy (0.7 Gy per fraction) to the gross disease, total dose 65 Gy in 26 fractions.
Trial: 10802368
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment technique (CTT) radiation therapy, 70.8 Gy in 38 fractions.
Trial: 10802368
Drug: Concomitant boost
RxNorm normalized name: BOOST
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant boost technique (CBT) radiation therapy.
Trial: 10802368
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment technique (CTT) radiation therapy.
Trial: 8623995
Drug: Group 1:
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Group 1: 75 mg intramuscular diclofenac, 1000 mg intravenous metamizole, 5.3 +/- 1 mg epidural morphine, and 15-20 ml mepivacaine 1% administered 85 +/- 41 min before skin incision. Epidural analgesia maintained by injections of 0.1 ml.kg‐1.h‐1 mepivacaine 1%.
Trial: 3912367
Drug: Oral cephradine
RxNorm normalized name: Cephradine
DrugBank: Cefradine (DB01333)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral cephradine
Trial: 3912367
Drug: Other antibiotics
RxNorm normalized name: Other antibiotics for topical use
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other antibiotics after cephradine
Trial: 27321485
Drug: Surgical intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical intervention model including antituberculosis drugs for at least 3 weeks, accurate wound assessment, complete excision of sinus tract and surrounding devitalized tissue, vacuum sealing drainage (VSD) for 1 to 2 weeks, followed by direct suture or grafting skin or flap.
Trial: 27321485
Drug: Routine dressing
RxNorm normalized name: DRESSING
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine dressing change every 3 days after initial antituberculosis drugs for at least 3 weeks.
Trial: 17315155
Drug: Low-dose cytarabine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose cytarabine (Ara-C) (20 mg twice daily for 10 days)
Trial: 15471181
Drug: Extracorporeal shockwave
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal shockwave therapy (ESWT) with 2 x 2000 impulses of 0.28 mJ/mm2 at an interval of two weeks
Trial: 3170089
Drug: Beta-carotene supplementation
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beta-carotene supplementation of 20 mg a day
Trial: 17466492
Drug: Paliperidone ER
RxNorm normalized name: Paliperidone ER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paliperidone ER 15 mg
Trial: 15887835
Drug: Gatifloxacin 400mg
RxNorm normalized name: GATIFLOXACIN 400MG TAB
DrugBank: Gatifloxacin (DB01044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gatifloxacin 400mg single oral dose
Trial: 9307648
Drug: Topical 50
RxNorm normalized name: urea topical 50% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 50 micrograms/ml latanoprost once daily from day 4 to day 18
Trial: 9307648
Drug: Placebo eye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo eye drops once daily from day 4 to day 18
Trial: 7294185
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of haloperidol
Trial: 7294185
Drug: Moderate dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moderate dose of haloperidol
Trial: 7294185
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose of haloperidol
Trial: 31468106
Drug: Strength and
RxNorm normalized name: Excedrin Extra Strength and Excedrin Tension Headache KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Strength and balance training intervention (2 months, once-weekly home-based)
Trial: 25954110
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy (AGITG MAX trial)
Trial: 25954110
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy (TRACC registry)
Trial: 25954110
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (AGITG MAX trial)
Trial: 25954110
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (TRACC registry)
Trial: 25954110
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy (TRACC registry, patients without peritoneal metastases)
Trial: 25954110
Drug: Chemotherapy alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy alone (TRACC registry, patients without peritoneal metastases)
Trial: 25954110
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy (MAX trial)
Trial: 25954110
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy (TRACC)
Trial: 25954110
Drug: Bevacizumab +
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Bevacizumab + chemotherapy (NSWCC)
Trial: 25954110
Drug: Chemotherapy duration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy duration
Trial: 17014595
Drug: Duloxetine 120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Duloxetine 120 mg once daily (QD)
Trial: 9820371
Drug: Endoscopic hemostasis
RxNorm normalized name: collagen hemostat
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endoscopic hemostasis (heater probe, bipolar electrocoagulation, or injection sclerosis)
Trial: 9820371
Drug: Medical‐surgical treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical‐surgical treatment
Trial: 8022739
Drug: Oral administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral administration of methylprednisolone (500 mg for three consecutive days)
Trial: 8022739
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of methylprednisolone (500 mg for three consecutive days)
Trial: 28490356
Drug: Miriplatin/DDP‐H combination
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miriplatin/DDP‐H combination therapy
Trial: 28490356
Drug: Miriplatin monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Miriplatin monotherapy
Trial: 25809331
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose CT colonography with enhanced scanning
Trial: 25809331
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose CT colonography with enhanced scanning
Trial: 25809331
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose CT colonography
Trial: 25809331
Drug: Conventional dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional dose CT colonography
Trial: 15098379
Drug: Raloxifene (Evista),
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Raloxifene (Evista), one tablet daily, with or without food
Trial: 7597427
Drug: Paclitaxel 135
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel 135 mg/m2 infused as a single dose over 1 hour
Trial: 7597427
Drug: Paclitaxel divided
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paclitaxel divided into three doses infused over 1 hour on 3 consecutive days
Trial: 7597427
Drug: Both infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Both infusion schedules
Trial: 2512129
Drug: Oral Ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral Ciprofloxacin (30mg/kg/day; max 1,500mg) for four weeks after initial therapy
Trial: 28261001
Drug: Cranberry extract
RxNorm normalized name: CRANBERRY EXTRACT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cranberry extract 1200 mg for 6 weeks
Trial: 24100691
Drug: Sparrow® drug‐eluting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sparrow® drug‐eluting stent (DES)
Trial: 18298503
Drug: Music therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Music therapy for 2 weeks
Trial: 17201647
Drug: Phenylephrine (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phenylephrine (20 mg)
Trial: 12492451
Drug: Bendroflumethiazide (TD)
RxNorm normalized name: Bendroflumethiazide
DrugBank: Bendroflumethiazide (DB00436)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bendroflumethiazide (TD) 5 mg/day
Trial: 9059313
Drug: NG-Monomethyl-L-arginine
RxNorm normalized name: NG-Monomethyl-L-arginine
DrugBank: Tilarginine (DB11815)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-Monomethyl-L-arginine
Trial: 2859870
Drug: Indoramin (25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indoramin (25 mg three times daily)
Trial: 2859870
Drug: Control (beta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (beta blockers and nitrates continued unchanged)
Trial: 22672770
Drug: Solanezumab 400
RxNorm normalized name: Galcanezumab
DrugBank: Galcanezumab (DB14042)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Solanezumab 400 mg weekly
Trial: 22672770
Drug: Solanezumab (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solanezumab (various doses)
Trial: 12354424
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy in hospitals with coronary revascularization capability
Trial: 12354424
Drug: Fibrinolytic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fibrinolytic therapy in hospitals without coronary revascularization capability
Trial: 1970584
Drug: Terfenadine (120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Terfenadine (120 mg oral)
Trial: 7069504
Drug: L-methionine (0.0605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-methionine (0.0605 mmoles/kg body weight)
Trial: 7069504
Drug: N-acetyl-L-methionine (0.0605
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-methionine (0.0605 mmoles/kg body weight)
Trial: 7069504
Drug: L-methionine and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-methionine and N-acetyl-L-methionine
Trial: 7069504
Drug: N-acetyl-L-methionine
RxNorm normalized name: N-acetyl-methionine, DL-
DrugBank: N-Acetylmethionine (DB01646)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-methionine
Trial: 23045575
Drug: Cognitive Behavioral
RxNorm normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive Behavioral Therapy and Physical Exercise (CBT/PE)
Trial: 15530150
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (1.35 g n‐3 fatty acids)
Trial: 9692655
Drug: Cimetidine 400
RxNorm normalized name: cimetidine 400 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 400 mg twice/day
Trial: 7841566
Drug: Nimodipine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 0.4 mg/h
Trial: 7841566
Drug: Nimodipine 1
RxNorm normalized name: nimodipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 1 mg/h
Trial: 7841566
Drug: Vehicle 10
RxNorm normalized name: meningococcal group B vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle 10 mL/h
Trial: 7841566
Drug: Placebo 10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 10 mL/h
Trial: 7841566
Drug: Nimodipine 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nimodipine 0.4 mg/h and 1 mg/h
Trial: 3073766
Drug: Intraarterial infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraarterial infusion therapy with prostaglandin E1 (PGE)
Trial: 3073766
Drug: Infusion therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion therapy with energy rich phosphates (ERP)
Trial: 29968385
Drug: Fixed-dose combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed-dose combination of oral drotaverine hydrochloride (80 mg) and paracetamol (500 mg)
Trial: 29968385
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (500 mg) three times a day for 3 days
Trial: 28448784
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (MI) telephone intervention conducted by pharmacy students, including an initial call and 5 monthly follow-up calls.
Trial: 25614134
Drug: Placebo HILT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo HILT (sham therapy group)
Trial: 17052306
Drug: Budesonide 200
RxNorm normalized name: budesonide 200 mcg/inh inhalation powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Budesonide 200 microg (for patients aged<11 years) or 400 microg administered via Turbuhaler
Trial: 18405951
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus usual asthma therapy
Trial: 11011847
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg folic acid, 0.4 mg vitamin B12 and 50 mg vitamin B6
Trial: 9309533
Drug: Naltrexone 50
RxNorm normalized name: naltrexone 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naltrexone 50 mg/die orally for 7 days
Trial: 8339552
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of dietary changes and exercise
Trial: 3730230
Drug: Alcuronium 0.15,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.15, 0.2 or 0.3 mg kg‐1 with priming
Trial: 3730230
Drug: Alcuronium 0.04
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.04 mg kg‐1 given 30 s after induction